591 related articles for article (PubMed ID: 32089500)
1. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Caraballo Galva LD; Cai L; Shao Y; He Y
J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
Jiang Y; Han QJ; Zhang J
World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
5. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
6. Adoptive cell transfer therapy for hepatocellular carcinoma.
Zhang R; Zhang Z; Liu Z; Wei D; Wu X; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):3-11. PubMed ID: 30659408
[TBL] [Abstract][Full Text] [Related]
7. Application of adoptive cell therapy in hepatocellular carcinoma.
Wu D; Li Y
Immunology; 2023 Dec; 170(4):453-469. PubMed ID: 37435926
[TBL] [Abstract][Full Text] [Related]
8. Potential of immunotherapy for hepatocellular carcinoma.
Breous E; Thimme R
J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
[TBL] [Abstract][Full Text] [Related]
9. T Cell-Associated Immunotherapy for Hepatocellular Carcinoma.
Ma W; Wu L; Zhou F; Hong Z; Yuan Y; Liu Z
Cell Physiol Biochem; 2017; 41(2):609-622. PubMed ID: 28214839
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for hepatocellular carcinoma.
Zongyi Y; Xiaowu L
Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
Büttner N; Schmidt N; Thimme R
Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
[TBL] [Abstract][Full Text] [Related]
12. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
13. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
14. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
16. T-cell-associated immunotherapy: a promising strategy for the treatment of hepatocellular carcinoma.
Ma W; Chen X; Yuan Y
Immunotherapy; 2017 Jun; 9(7):523-525. PubMed ID: 28595519
[No Abstract] [Full Text] [Related]
17. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
18. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go.
Wang K; Wang C; Jiang H; Zhang Y; Lin W; Mo J; Jin C
Front Immunol; 2021; 12():792781. PubMed ID: 34975896
[TBL] [Abstract][Full Text] [Related]
19. Prospects and Challenges for T Cell-Based Therapies of HCC.
Woller N; Engelskircher SA; Wirth T; Wedemeyer H
Cells; 2021 Jun; 10(7):. PubMed ID: 34209393
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
Repáraz D; Aparicio B; Llopiz D; Hervás-Stubbs S; Sarobe P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]